The article highlights the potentially game-changing approach of the Company towards treating Alzheimer’s Disease, based on technology developed at Rutgers by Dr. Luciano D’Adamio, PhD, MD, New Jersey ...

antibody- or complement-dependent cell-mediated cytotoxicity; and reverse signaling through ligation with transmembrane TNF. By blocking TNF, these agents may lead to serious adverse affects.

Tumor necrosis factor (TNF)-alpha, a proinflammatory cytokine, has been implicated in the pathogenesis of AD. Objective: To investigate the use of a biologic TNF-alpha inhibitor, etanercept was ...

Sino Biological offers a comprehensive selection of recombinant TNF and TNFR proteins and corresponding antibodies that support drug discovery and development research on TNFs/TNFRs. TNFRSF ...

The therapeutic antibody industry has been propelled by the success of the 'big 5': the tumour necrosis factor (TNF)-specific antibodies infliximab (Remicade; Centocor/Merck) and adalimumab ...

Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.

Accord BioPharma Inc., the U.S. specialty division of Intas Pharmaceuticals Ltd., has reached an exclusive commercialization and license agreement with Bio-Thera Solutions for BAT2506, a biosimilar ...

Bio-Thera had entered into an exclusive licensing agreement with STADA Arzneimittel AG to commercialize BAT2506 in the European Union (UK), the United Kingdom (UK), Switzerland, and selected other ...